T-Cell Non-Hodgkin Lymphoma — Trials

T-Cell Non-Hodgkin Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

1,008 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 225
Recruiting: 127
Ph III recruiting: 9
Growth YoY: +23.4%
Industry share: 21%
Top sponsor: Institute of Hematology & Blood Diseases Hospital, China
Termination share: 35.1%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (169)

clinicaltrialsPublishedShowing 201–250 of 519 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06492629	Toripalimab Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-Cell Lymphoma	unknown	Phase 2	43	Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER	1	Jul 9, 2024	clinicaltrials
NCT05105412	Lenalidomide and Gemcitabine in Relapsed or Refractory Peripheral T-cell Lymphomas	terminated	Phase 1 / Phase 2	12	National Health Research Institutes, TaiwanOTHER	1	Jul 8, 2024